REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals expects to report an acquired in-process research and development (IPR&D) charge of approximately $127 million on a pre-tax basis for the second quarter of 2026. This charge, resulting from collaboration and licensing agreements, is anticipated to negatively impact both GAAP and non-GAAP net income per diluted share by about $1.00. The company emphasized that these preliminary estimates are unaudited and subject to finalization procedures.

Regeneron Pharmaceuticals, Inc. announced it will release its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time on the same day to discuss the results. A replay and transcript of the event will be available on Regeneron's website.

Regeneron announced that the FDA and EMA have accepted regulatory applications for cemdisiran to treat adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA granted Priority Review with a target action date in November 2026, utilizing a Priority Review Voucher. A decision from the European Commission is expected in the second half of 2027, with a Japanese filing planned for early 2027.

Regeneron Pharmaceuticals announced that maftivimab, a component of its FDA-approved Ebola treatment Inmazeb, has been recommended by the World Health Organization's (WHO) Therapeutics Advisory Group for prioritized evaluation in clinical trials for Bundibugyo ebolavirus. This recommendation follows WHO's declaration of a public health emergency due to the current Bundibugyo virus outbreak in the Democratic Republic of the Congo and Uganda. Regeneron is coordinating with the U.S. Department of Health and Human Services and WHO to advance clinical evaluation and is preparing existing maftivimab supply for potential trials.

Regeneron announced positive Phase 1/2 LINKER-AL2 trial results for Lynozyfic (linvoseltamab) in second-line-plus systemic AL amyloidosis. The trial showed a 100% hematologic complete response (CR) rate at the highest tested dose and 71% CR at the lower dose, significantly outperforming the 53% CR rate of standard-of-care in untreated patients. Additionally, a majority of patients with renal (73%) or cardiac (50%) involvement demonstrated improved organ function. The Phase 2 portion of the trial, with registrational intent, is currently underway, and these results will be presented at the ASCO 2026 Annual Meeting.

Regeneron Pharmaceuticals announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates using Parabilis' Helicon peptide platform, specifically Antibody-Helicon Conjugates (AHCs). This partnership aims to target challenging and historically "undruggable" intracellular proteins. Regeneron will provide $125 million to Parabilis, consisting of a $50 million upfront payment and a $75 million equity commitment, with potential for up to $2.2 billion in additional milestone payments and tiered royalties.

Regeneron Pharmaceuticals announced that its Phase 3 trial evaluating fianlimab in combination with cemiplimab as a first-line treatment for unresectable locally advanced or metastatic melanoma did not meet its primary endpoint of statistical significance for progression-free survival (PFS). Despite the miss, a numeric improvement of 5.1 months in median PFS was observed for the high-dose combination compared to pembrolizumab monotherapy. No new safety signals were identified, and a head-to-head Phase 3 trial against Opdualag is currently underway.

Regeneron Pharmaceuticals and Society for Science announced the winners of the Regeneron International Science and Engineering Fair (ISEF) 2026. Hikaru Kuribayashi, 17, received the $100,000 George D. Yancopoulos Innovator Award for his simulation program. Lakshmi Agrawal and Nikola Veselinov each won $75,000 Regeneron Young Scientist Awards. The competition awarded over $7 million in total prizes to more than 1,700 students from over 67 countries, highlighting Regeneron's significant investment in fostering future STEM leaders.

Regeneron Pharmaceuticals announced its inclusion in the Dow Jones Best-in-Class World Index and North America Index, recognizing its corporate sustainability performance. This marks its sixth consecutive year on the North America Index and highlights its commitment to responsibility, exemplified by offering a new gene therapy for genetic hearing loss for free in the U.S. The company also introduced new 2030 science-led responsibility goals and detailed progress in its 2025 Responsibility Report, while continuing its significant STEM education investments.

Regeneron and Sanofi presented positive results from the REMODEL Phase 4 trial for Dupixent in adult patients with eosinophilic esophagitis (EoE). The trial demonstrated significant and clinically meaningful improvements in esophageal distensibility and disease-related structural changes compared to placebo at week 24. These findings reinforce Dupixent's role as the leading biologic treatment for EoE by addressing underlying inflammation and symptoms.